Evidence map›Paper›PMID 29688452›Full record

ArticleGigaScience2018

Differential protein expression and post-translational modifications in metronidazole-resistant Giardia duodenalis.

Samantha J Emery, Louise Baker, Brendan R E Ansell, Mehdi Mirzaei, Paul A Haynes, Malcom J McConville, Staffan G Svärd, Aaron R Jex

Open access · goldAbstract read
In one paragraph

Article in GigaScience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. First Characterization and Zoonotic Potential Evaluation ofTransboundary and emerging diseases · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Characterization of Metronidazole-ResistantFrontiers in microbiology · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Nitroreductase Activites inPathogens (Basel, Switzerland) · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Samantha J EmeryPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Louise BakerPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Brendan R E AnsellPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Mehdi MirzaeiChemistry and Biomolecular Sciences, Faculty of Science, Macquarie University, North Ryde, NSW, Australia.
Paul A HaynesChemistry and Biomolecular Sciences, Faculty of Science, Macquarie University, North Ryde, NSW, Australia.
Malcom J McConvilleBio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, Australia.
Staffan G SvärdDepartment of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
Aaron R JexPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
University of Melbourne · AUMacquarie University · AUWalter and Eliza Hall Institute of Medical Research · AUUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metronidazole (Mtz) is the frontline drug treatment for multiple anaerobic pathogens, including the gastrointestinal protist, Giardia duodenalis. However, treatment failure is common and linked to in vivo drug resistance. In Giardia, in vitro drug-resistant lines allow controlled experimental interrogation of resistance mechanisms in isogenic cultures. However, resistance-associated changes are inconsistent between lines, phenotypic data are incomplete, and resistance is rarely genetically fixed, highlighted by reversion to sensitivity after drug selection ceases or via passage through the life cycle. Comprehensive quantitative approaches are required to resolve isolate variability, fully define Mtz resistance phenotypes, and explore the role of post-translational modifications therein. Findings: We performed quantitative proteomics to describe differentially expressed proteins in 3 seminal Mtz-resistant lines compared to their isogenic, Mtz-susceptible, parental line. We also probed changes in post-translational modifications including protein acetylation, methylation, ubiquitination, and phosphorylation via immunoblotting. We quantified more than 1,000 proteins in each genotype, recording substantial genotypic variation in differentially expressed proteins between isotypes. Our data confirm substantial changes in the antioxidant network, glycolysis, and electron transport and indicate links between protein acetylation and Mtz resistance, including cross-resistance to deacetylase inhibitor trichostatin A in Mtz-resistant lines. Finally, we performed the first controlled, longitudinal study of Mtz resistance stability, monitoring lines after cessation of drug selection, revealing isolate-dependent phenotypic plasticity. Conclusions: Our data demonstrate understanding that Mtz resistance must be broadened to post-transcriptional and post-translational responses and that Mtz resistance is polygenic, driven by isolate-dependent variation, and is correlated with changes in protein acetylation networks.

Indexed as

Drug ResistanceAntiprotozoal AgentsGiardia lambliaMetronidazoleProtein Processing, Post-TranslationalProtozoan ProteinsAntiprotozoal AgentsMetronidazoleProtozoan Proteins

Identifiers

PMID29688452
PMCPMC5913674
OpenAlexW2789557047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.